Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.

Hepatology research : the official journal of the Japan Society of Hepatology（2023）

引用 2|浏览17

暂无评分

摘要

SOF/VEL therapy may suppress the development of decompensated events and improve the prognosis in decompensated cirrhotic patients; however, the incidence of HCC remains prevalent in these patients irrespective of SOF/VEL therapy.

查看译文

关键词

HCV,decompensated event,decompensated liver cirrhosis,direct-acting antiviral,hepatocellular carcinoma,survival

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要